<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="140514">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271725</url>
  </required_header>
  <id_info>
    <org_study_id>1200.98</org_study_id>
    <secondary_id>2010-021945-29</secondary_id>
    <nct_id>NCT01271725</nct_id>
  </id_info>
  <brief_title>LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures</brief_title>
  <official_title>LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Treatment Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The general aim of this study is to investigate the efficacy and safety of afatinib (BIBW
      2992) alone and in combination with weekly paclitaxel or weekly vinorelbine (in patients who
      progress on afatinib monotherapy within this trial) as treatment in patients with
      HER2-overexpressing, metastatic breast cancer, who failed HER2-targeted treatment in the
      neoadjuvant or adjuvant setting
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response (OR) assessed by RECIST 1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1)</measure>
    <time_frame>every 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response during each treatment period according to RECIST 1.1</measure>
    <time_frame>Every 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response, defined as the time from first objective response to the time of progression or death.</measure>
    <time_frame>Every 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the severity and incidence of adverse event according to Common Terminology Criteria for Adverse Events (CTC s, AE Version 3.0), changes in vital signs and safety laboratory parameters</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Afatinib 40mg once daily (OD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel 80 mg/m2 weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vinorelbine 25 mg/m2 weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine 25 mg/m2 weekly</intervention_name>
    <description>Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy</description>
    <arm_group_label>Vinorelbine 25 mg/m2 weekly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib 40mg once daily (OD)</intervention_name>
    <description>Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease</description>
    <arm_group_label>Afatinib 40mg once daily (OD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel 80 mg/m2 weekly</intervention_name>
    <description>Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy</description>
    <arm_group_label>Paclitaxel 80 mg/m2 weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Female patients &gt;=18 years with proven diagnosis of HER2-overexpressing,
             histologically confirmed breast cancer

          2. Stage IV metastatic disease

          3. At least one measurable lesion according to RECIST 1.1 (Response Evaluation Criteria
             for Solid Tumours version 1.1). Skin, bone and brain lesions are considered
             non-target lesions

          4. Must have failed or progressed on either trastuzumab or lapatinib or trastuzumab and
             lapatinib treatment in the neoadjuvant and/or adjuvant setting

        Exclusion criteria:

          1. Prior first line therapy for metastatic breast cancer

          2. Known pre-existing interstitial lung disease

          3. Active brain metastases

          4. History or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure NYHA classification of 3,
             unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6
             months prior to trial treatment.

          5. Cardiac left ventricular function with resting ejection fraction of less than 50%.

          6. Prior treatment with EGFR/HER2-targeted small molecules or antibodies other than
             trastuzumab and lapatinib in the neoadjuvant or adjuvant setting

          7. Prior treatment with paclitaxel in the past 12 months

          8. Must not have received prior vinorelbine treatment

          9. Inadequate hepatic, renal and haematologique organ function
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1200.98.85202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.85201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amravati</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thiruvananthapuram</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.07014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.07013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.07012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.07008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.07011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sochi</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stavropol</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.88607 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.88602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.88604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.88605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barnstaple</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.98.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Romania</country>
  </removed_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 3, 2016</lastchanged_date>
  <firstreceived_date>January 6, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
